Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome

NCT05361668 is registered in ClinicalTrials.gov with Crinetics Pharmaceuticals Inc. as lead sponsor.

NCT NCT05361668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05361668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome
Lead sponsor
Crinetics Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 22, 2022
Completion date
February 24, 2026
Enrollment
36 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid, carcinoid intestine tumor, carcinoid syndrome, carcinoid syndrome diarrhea, carcinoid tumor, carcinoid tumor of cecum, carcinoid tumor of ileum, carcinoid tumor of liver, carcinoid tumor of pancreas